The Endocrine Society has published a sweeping scientific statement — "Obesity Science, Research Gaps, and Opportunities in the New Era of Obesity Medicines" — calling out what we still don't know about obesity treatment, even as powerful new drugs reshape the field. Lead author Dr. Daniel Drucker of the University of Toronto emphasized that while GLP-1s and similar medications have been transformative, critical questions remain about how to optimize and individualize their use.

The statement is intentionally non-prescriptive — it's designed to frame the science, highlight gaps, and set the research agenda rather than dictate clinical practice. Alongside the publication, the Endocrine Society launched its new Center on Obesity, a hub for members featuring curated research, advocacy resources, and educational tools. A new clinical practice guideline on obesity pharmacotherapy is also in the works, expected in early 2027.

Key Takeaways:

• Six research priorities identified: pathophysiology of fat regulation, heterogeneity of treatment response, redefining success beyond weight loss, understanding drug response over time, health outcomes with pharmacotherapy, and long-term safety of new obesity medicines
• BMI and percent weight loss alone are insufficient measures of obesity treatment success
• Racial and ethnic differences in adiposity and complication risk were flagged as underrepresented in the statement

Why it matters: With one in eight people worldwide living with obesity, and a new generation of medicines rapidly entering the market, this statement gives clinicians and researchers a shared roadmap — helping the field move from trial-and-error to evidence-based, individualized care.